A 54-year-old man was diagnosed with atypical haemolytic uraemic syndrome (aHUS) with confirmed complement H mutation in 2012, requiring ongoing dialysis. He was commenced on eculizumab in 2014 once the pharmaceutical board approved this drug. After 4 months, he received a live unrelated donor renal transplant from his wife and continued eculizumab post-transplant. Three months later, there was a rise in his creatinine with no laboratory features of haemolysis and a kidney biopsy confirmed rejection, which was treated with increased immunosuppression. After completing 12 months of treatment with eculizumab, he opted for close monitoring rather than continuation with therapy. Five months post-cessation of the drug, there was a rise in creatinine, and once again, haematological parameters remained within reference range; however, his kidney biopsy showed features consistent with recurrence of aHUS; hence, eculizumab was recommenced with good effect. While there was no evidence of haemolysis, there was a gradual rise in LDH level and a drop in platelet count, although the parameters remained within the normal range. This suggests that aHUS can recur in the allograft in the absence of haematological abnormalities. Clinicians should have a low threshold for allograft biopsy if haematological parameters are not just outside the reference range, but possibly also if there are changes of at least >25% from baseline in platelet count and LDH levels, particularly in those patients who are no longer eligible for eculizumab. ). The plasma level of ADAMTS13 was over 10%, thereby excluding thrombotic thrombocytopaenic purpura and confirming the diagnosis of atypical haemolytic uraemic syndrome (aHUS). A kidney biopsy showed focal necrotizing lesions with capillary occlusion by red cell fragments, fibrin and neutrophils, indicative of thrombotic microangiopathy (TMA). Despite treatment with intravenous corticosteroids and alternate daily plasmapheresis (exchanged with fresh frozen plasma) over a 2 week period, there was ongoing evidence of MAHA, and he remained dialysis-dependent. Genetic screening performed in the Clinical Research Center for Rare Diseases in Italy identified the presence of a heterozygous complement factor H mutation, located at exon 23 (codon 3644G > A). Combined liverkidney transplantation was considered 12 months later, but given the presence of moderate-severe pulmonary hypertension, possibly related to his large arterio-venous fistula-related shunt, as well as concomitant cardiovascular disease, he was deemed unsuitable for dual transplantation. With Pharmaceutical Benefits Advisory Committee (PBAC) approving the use of eculizumab for aHUS from December 2014,
ABSTRACT:
A 54-year-old man was diagnosed with atypical haemolytic uraemic syndrome (aHUS) with confirmed complement H mutation in 2012, requiring ongoing dialysis. He was commenced on eculizumab in 2014 once the pharmaceutical board approved this drug. After 4 months, he received a live unrelated donor renal transplant from his wife and continued eculizumab post-transplant. Three months later, there was a rise in his creatinine with no laboratory features of haemolysis and a kidney biopsy confirmed rejection, which was treated with increased immunosuppression. After completing 12 months of treatment with eculizumab, he opted for close monitoring rather than continuation with therapy. Five months post-cessation of the drug, there was a rise in creatinine, and once again, haematological parameters remained within reference range; however, his kidney biopsy showed features consistent with recurrence of aHUS; hence, eculizumab was recommenced with good effect. While there was no evidence of haemolysis, there was a gradual rise in LDH level and a drop in platelet count, although the parameters remained within the normal range. This suggests that aHUS can recur in the allograft in the absence of haematological abnormalities. Clinicians should have a low threshold for allograft biopsy if haematological parameters are not just outside the reference range, but possibly also if there are changes of at least >25% from baseline in platelet count and LDH levels, particularly in those patients who are no longer eligible for eculizumab.
CASE REPORT
A 54-year-old man presented in March 2012 with acute kidney injury requiring dialysis at presentation (creatinine 950 μmol/L (normal range 60-110 μmol/L)) and severe new-onset hypertension (blood pressure of 230/120 mmHg) with associated blurred vision and headache. Investigations revealed an active urine sediment, proteinuria, thrombocytopaenia (platelet count of 70 × 10 9 /L (normal range 150-400 × 10 9 /L]) and haematological and biochemical abnormalities consistent with microangiopathic haemolytic anaemia (MAHA; anaemia with haemoglobin of 87 g/L (normal range 135-180 g/L), red cell fragments on blood film, elevated lactate dehydrogenase (LDH) of 2700 U/L (normal range 310-620 U/L) and reduced haptoglobins of <0.07 g/L (normal range 0.30-2.00 g/L)). The plasma level of ADAMTS13 was over 10%, thereby excluding thrombotic thrombocytopaenic purpura and confirming the diagnosis of atypical haemolytic uraemic syndrome (aHUS). A kidney biopsy showed focal necrotizing lesions with capillary occlusion by red cell fragments, fibrin and neutrophils, indicative of thrombotic microangiopathy (TMA). Despite treatment with intravenous corticosteroids and alternate daily plasmapheresis (exchanged with fresh frozen plasma) over a 2 week period, there was ongoing evidence of MAHA, and he remained dialysis-dependent. Genetic screening performed in the Clinical Research Center for Rare Diseases in Italy identified the presence of a heterozygous complement factor H mutation, located at exon 23 (codon 3644G > A). Combined liverkidney transplantation was considered 12 months later, but given the presence of moderate-severe pulmonary hypertension, possibly related to his large arterio-venous fistula-related shunt, as well as concomitant cardiovascular disease, he was deemed unsuitable for dual transplantation. With Pharmaceutical Benefits Advisory Committee (PBAC) approving the use of eculizumab for aHUS from December 2014, treatment was initiated at a dose of 900 mg, followed by 1200 mg fortnightly (evidence of ongoing MAHA and thrombocytopaenia at treatment initiation). Once he was deemed to be in clinical remission following introduction of eculizumab, he received a live-unrelated donor kidney transplant from his wife 4 months later. He had received induction therapy with interleukin-2-receptor antibody (basiliximab 20 mg days 0 and 4), followed by maintenance immunosuppression of prednisolone (weaning to 10 mg by month 3), mycophenolic-sodium (720 mg twice daily) and tacrolimus (aiming for trough level of 5-8 ng/mL). He continued on fortnightly eculizumab after transplantation, as well as at least weekly monitoring of full blood count and film, LDH and haptoglobin. At 3 months post-transplant, he developed acute graft deterioration with creatinine increasing from a baseline of 140 to 200 μmol/L. There was no evidence of MAHA or thrombocytopaenia (Table 1 ). An allograft biopsy demonstrated histological features consistent with Banff Grade 3 cellular rejection. He received pulse intravenous methylprednisolone with improvement of his graft function to baseline. Re-evaluation of the use of eculizumab by the PBAC in December 2015 had resulted in an extension of treatment for aHUS aHUS recurrence in allograft without MAHA from 12 to 24 months. However, the patient declined treatment continuation after completing 12 months of eculizumab and, instead, opted for close monitoring (weekly for 3 months and then fortnightly investigations including full blood count, blood film, LDH and haptoglobin) for disease recurrence. At 17 months post-transplant (i.e. 5 months following cessation of eculizumab), he developed an acute deterioration in his graft function with creatinine increasing from 150 to 204 μmol/L. Although there was no evidence of thrombocytopaenia or evidence of MAHA, there was a gradual increase in plasma LDH level and reduction of platelet count and haptoglobin from 1 month post-transplant (still on eculizumab treatment) to the current presentation (Table 1 ). An allograft biopsy showed histological features consistent with TMA, with evidence of fibrinoid necrosis of several arterioles and smaller muscular arteries along with mesangiolysis and reduplication of the basement membrane (Image 1). Eculizumab was initiated following approval by PBAC, with immediate improvement in his graft function. His creatinine has returned to a baseline of 150 μmol/L 1 month following the re-introduction of eculizumab.
DISCUSSION
Atypical HUS is a genetic condition of uncontrolled alternative complement pathway activation, characterized by a clinical triad of MAHA, thrombocytopenia and acute kidney injury. The presence of complement regulatory proteins averts uncontrolled complement pathway activation, providing a means for the immune system to prevent continuous complement activation and ongoing cell damage and vascular thrombosis. Hereditary aHUS may occur as a result of a loss of function mutation in a complement regulatory gene (CFH, CFI or CD46) or a gain of function mutation in an effector gene (CFB or C3), thereby preventing the degradation of these dysfunctional complement regulatory proteins.
1,2
Up to 60% of patients with aHUS have identifiable genetic mutations in complement genes or have anti-CFH autoantibodies, both of which result in uncontrolled complementmediated cell damage and development of TMA lesions. 3 Even though uncontrolled complement activation is pathognomonic of aHUS, serum complement levels are often normal with little prognostic significance. 4, 5 Certain genetic mutations, particularly those involving CFH, CFI and C3, are associated with the poorest clinical outcomes, with up to 80% risk of disease recurrence after kidney transplantation. 6 Eculizumab, a recombinant humanized C5 inhibitor, is the only Food and Drug Administration-approved agent that is effective in the treatment of aHUS by binding with high affinity to the complement protein C5 and, in so doing, prevents the generation of the membrane attack complex C5b-9 by inhibiting the cleavage of C5 to C5a and C5b. Several observational studies have shown that treatment with eculizumab in aHUS patients with progressive TMA or with chronic kidney disease resulted in haematological normalization, improved kidney function (with 80% becoming dialysis-independent) and prevented further TMA events. 7, 8 Nevertheless, it is important to point out that reversal of end-stage kidney disease induced by TMA may not always be possible highlighting the importance of early diagnosis and prompt treatment when aHUS is confirmed. Lifelong treatment with eculizumab is recommended because this agent only inhibits the terminal portion of the complement cascade without affecting early complement cascade activation. In addition, there are no identifiable intrinsic or extrinsic triggers that have been consistently shown to induce a TMA episode in patients with aHUS, and therefore, the possibility of discontinuing eculizumab safely in patients who have achieved complete remission following treatment with eculizumab remains unknown. In the pre-eculizumab era, the recommendation of kidney transplantation to patients with aHUS was controversial because of the high risk of disease recurrence resulting in early graft loss after transplantation. 9 With the introduction of eculizumab, clinicians and patients with aHUS have the opportunity to consider kidney transplantation as a potential treatment option for end-stage kidney disease, which would otherwise have not been possible without this agent. In addition, reversal of TMA in the allograft with the initiation of eculizumab in aHUS patients who have experienced disease recurrence after kidney transplantation further highlights the efficacy of this agent in reversing TMA events across the entire spectrum and severity of chronic kidney disease.
10
The monitoring for the development of TMA events or recurrent aHUS after kidney transplantation typically involves regular assessments of haematological and biochemical abnormalities, with unexplained drop in haemoglobin and platelet levels to below reference range, presence of red cell fragments accompanied by raised LDH levels and reduction in haptoglobin levels indicative of TMA/disease recurrence. However, the frequency of monitoring to detect subclinical disease
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recurrence remains unknown, particularly in patients who have discontinued treatment with eculizumab. In this patient, there were no haematological or biochemical abnormalities preceding disease recurrence, highlighting the deficiency of these laboratory investigations in identifying at risk patients. However, there was over a 40% reduction in his platelet count and over a twofold increase in LDH level (although still within normal range) from early post-transplant during eculizumab cover to the current presentation, suggesting that a change in these parameters from baseline may provide the first clinical clue in the onset of subclinical TMA/disease recurrence. The lack of a concurrent reduction in haemoglobin or evidence of red cell fragments on blood film may indicate that these parameters are less sensitive in detecting subclinical disease compared with platelet count and LDH level. Although a similar case has been reported in a 12-year-old patient with aHUS, there was ambiguity in the precise nature of graft dysfunction/loss in this patient, which was more likely related to antibody-mediated rejection rather than disease recurrence. 11 Our patient is now eligible for another 12 months of eculizumab, with uncertainty on whether he will be eligible for continuation, considering the development of early disease recurrence after transplantation. If he is not eligible for drug continuation, he will undergo more stringent monitoring with one to two weekly checks of full blood count, blood film, creatinine, LDH and haptoglobin, with a low threshold for allograft biopsy if any of the previous parameters are abnormal (i.e. outside normal range) or if there are substantial change of at least >25% from baseline in platelet count and LDH level.
CONCLUSION
Thrombotic microangiopathy can recur in the allograft in the absence of thrombocytopaenia and MAHA. Clinicians should be cognizant of this deficiency during monitoring for TMA in patients with aHUS, particularly in those who are no longer eligible for eculizumab.
